CRP and lung carcinoma: For example, recent clinical trials found an anti-inflammatory Canakinumab, a monoclonal antibody for IL-1β, significantly reduced incidence of recurrent cardiovascular events as well as lung cancer in patients with previous myocardial infarction and elevated CRP [47,48].